Areva : The bears are taking over
Entry price | Target | Stop-loss | Potential |
---|
€4.61 |
€4 |
€5.06 |
+13.31% |
---|
The technical chart pattern of stocks in Areva suggests a continuation of the underlying downward trend, which has already been in place for a number of trading sessions.
Summary● The company usually posts poor financials for mid or long term investments.
Strengths● Share prices are approaching a strong support area in daily data, which offers good timing for investors.
Weaknesses● According to Thomson-Reuters' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
● Low profitability weakens the company.
● The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
● Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
● The company's earnings releases usually do not meet expectations.
● For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
● For the past year, analysts have significantly revised downwards their profit estimates.
● Most analysts recommend that the stock should be sold or reduced.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.